Trends in Bio-Medicine 2017

Biotechnology firms are part of emerging segments with great growth potential in the healthcare sector. Demand for effective treatments are rising along with how much people are willing to spend on their health-care. Treatment archetypes are evolving, and technological innovation in cell therapy and regenerative medicine will give the market even greater strength in the coming years.

Commercialization of Biologics

Global healthcare spending rose by 1.7% year-over-year in 2016, in correlation with an increase in incidence of chronic diseases. “This has led to a growth in the demand for biomedicine. Development of new drugs and the expected commercialization of pipeline drugs will further increase the market growth of biomedicine”, says Haim Toledano biotech investor. On the other side, operations costs, regulatory compliances, and supply chain complexity are all increasing, which presents a major challenge.Image result for Trends in Bio-Medicine 2017

Changing Healthcare Landscape

In 2015, North America accounted for a majority of the market share of global industry revenue. This was not predicted to be the case in the coming years, as markets in the Asia Pacific and Latin America continue to emerge. Biomedicine firms will need to adjust to structural shifts and adopt new operating models to deal with both the sluggish market growth rate in profitable North America, and also the emerging markets in other regions.

Current Major Players

“There are a number of key stakeholders in the biomedicine market right now to look out for”, says Haim Toledano. “These include Teva Pharmaceutical Industries, Quest Pharmatech, Apeiron Biologics AG, Sigma Aldrich, Sanofi S.A, Janssen Biotech, Inc and Mallinckrodt Pharmaceuticals”. These companies, and the companies that didn’t make this list, will need to keep upgrading their capabilities, both manufacturing and operation, in order to sustain the growth in the global market.

Gene Therapy

Research will continue to be focused on gene therapy, and more recently, gene editing, which fixes defective DNA. Trials are underway on this topic, and we will continue to see improvements and developments in this area.

Human Embryo Genome Editing

Human cell injection into animal embryos is set to be greenlit in the United States, pending reaction to the Chinese research and attempt to edit the DNA of a human embryo.

Alzheimer Medication and Solution

As the Baby Boomer population in North America continues to age, solutions become more and more demanded regarding Alzheimer’s treatment. While there are currently six medications available (only five in the United States) to treat the symptoms of Alzheimer’s; and there are currently no approved medicines for treating the underlying causes.

There are a few drugs currently in development that aim to change the disease process by impacting one or more of the wide-ranging changes that occur to the brain in Alzheimer’s patients. Beta-amyloid, the chief component of plaques that cause the brain abnormalities present in Alzheimer’s patients, may be able to be prevented from clumping into plaques, or could be cleared using antibodies.

One current drug in research that will target beta-amyloid is called Solanezumab. This is an antibody designed to lower the presence of beta-amyloid plaques by binding to the protein fragments and preventing the formation of plaques.

 

23426-13126-2014-06-04819967